12-month outcomes of HIV-infected infants identified at birth at one maternity site in Johannesburg, South Africa: an observational cohort study

The Lancet HIV

Volumn 5, Issue 12, 2018, Pages e706-e714

  Technau, Karl Günter ^a   Strehlau, Renate ^a   Patel, Faeezah ^a   Shiau, Stephanie ^a   Burke, Megan ^a   Conradie, Martie ^a   Sorour, Gillian ^a   Sherman, Gayle G ^a,c   Coovadia, Ashraf ^a   Murnane, Pamela M ^a,b,d   Abrams, Elaine J ^a,e   Kuhn, Louise ^a,b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

AGE; ANTIRETROVIRAL THERAPY; ARTICLE; CHILDBIRTH; COHORT ANALYSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GESTATIONAL AGE; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SOUTH AFRICA; VIRUS INHIBITION; VIRUS LOAD; ANIMAL; HOSPITAL; MOLECULAR DIAGNOSIS; NEWBORN; PATHOLOGY; PROCEDURES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANIMALS; ANTI-RETROVIRAL AGENTS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HOSPITALS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; POLYMERASE CHAIN REACTION; RETENTION IN CARE; SOUTH AFRICA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85058608525     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(18)30251-0     Document Type: Article

References (28)

1. Marston, M, Becquet, R, Zaba, B, et al. Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa. Int J Epidemiol 40 (2011), 385–396.
2. Violari, A, Cotton, MF, Gibb, DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 359 (2008), 2233–2244.
3. UNICEF Data. Global and regional trends. 2018, UNICEF, New York https://data.unicef.org/topic/hivaids/global-regional-trends/. (Accessed 5 April 2018)
4. Braitstein, P, Songok, J, Vreeman, RC, et al. “Wamepotea” (they have become lost): outcomes of HIV-positive and HIV-exposed children lost to follow-up from a large HIV treatment program in western Kenya. J Acquir Immune Defic Syndr 57 (2011), e40–e46.
5. Ciaranello, AL, Park, JE, Ramirez-Avila, L, Freedberg, KA, Walensky, RP, Leroy, V, Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med, 9, 2011, 59.
6. Barron, P, Pillay, Y, Doherty, T, et al. Eliminating mother-to-child HIV transmission in South Africa. Bull World Health Organ 91 (2013), 70–74.
7. Lilian, RR, Kalk, E, Technau, KG, Sherman, GG, Birth diagnosis of HIV infection in infants to reduce infant mortality and monitor for elimination of mother-to-child transmission. Pediatr Infect Dis J 32 (2013), 1080–1085.
8. Technau, KG, Kuhn, L, Coovadia, A, Carmona, S, Sherman, G, Improving early identification of HIV-infected neonates with birth PCR testing in a large urban hospital in Johannesburg, South Africa: successes and challenges. J Int AIDS Soc 20 (2017), 1–8.
9. Technau, KG, Kuhn, L, Coovadia, A, Murnane, PM, Sherman, G, Xpert HIV-1 point-of-care test for neonatal diagnosis of HIV in the birth testing programme of a maternity hospital: a field evaluation study. Lancet HIV 4 (2017), e442–e448.
10. Technau, KG, Mazanderani, AH, Kuhn, L, et al. Prevalence and outcomes of HIV-1 diagnostic challenges during universal birth testing—an urban South African observational cohort. J Int AIDS Soc, 20(suppl 6), 2017, 21761.
11. Rouet, F, Sakarovitch, C, Msellati, P, et al. Pediatric viral human immunodeficiency virus type 1 RNA levels, timing of infection, and disease progression in African HIV-1-infected children. Pediatrics, 112, 2003, e289.
12. McIntosh, K, Shevitz, A, Zaknun, D, et al. Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatric Infect Dis J 15 (1996), 1087–1091.
13. Shearer, WT, Quinn, TC, LaRussa, P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 336 (1997), 1337–1342.
14. Reitz, C, Coovadia, A, Ko, S, et al. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis 201 (2010), 1121–1131.
15. Porter, M, Davies, MA, Mapani, MK, et al. Outcomes of infants starting antiretroviral therapy in Southern Africa, 2004–2012. J Acquir Immune Defic Syndr 69 (2015), 593–601.
16. Frigati, L, Wynberg, E, Maritz, J, Holgate, S, Cotton, MF, Rabie, H, Antiretroviral treatment initiated in the first month of life. Pediatric Infect Dis J 36 (2017), 584–587.
17. Abrams, EJ, Woldesenbet, S, Soares Silva, J, et al. Despite access to antiretrovirals for prevention and treatment, high rates of mortality persist among HIV-infected infants and young children. Pediatric Infect Dis J 36 (2017), 595–601.
18. Peltzer, K, Mlambo, G, Factors determining HIV viral testing of infants in the context of mother-to-child transmission. Acta Paediatr 99 (2010), 590–596.
19. Feinstein, L, Edmonds, A, Okitolonda, V, et al. Implementation and operational research: maternal combination antiretroviral therapy is associated with improved retention of HIV-exposed infants in Kinshasa, Democratic Republic of Congo. J Acquir Immune Deficiency Syndr 69 (2015), e93–e99.
20. Chetty, T, Knight, S, Giddy, J, Crankshaw, TL, Butler, LM, Newell, ML, A retrospective study of human immunodeficiency virus transmission, mortality and loss to follow-up among infants in the first 18 months of life in a prevention of mother-to-child transmission programme in an urban hospital in KwaZulu-Natal, South Africa. BMC Pediatr, 12, 2012, 146.
21. Cotton, MF, Holgate, S, Nelson, A, Rabie, H, Wedderburn, C, Mirochnick, M, The last and first frontier—emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants. J Int AIDS Soc, 18(suppl 6), 2015, 20271.
22. Mazanderani, AH, Moyo, F, Kufa, T, Sherman, GG, Brief report: declining baseline viremia and escalating discordant HIV-1 confirmatory results within South Africa's early infant diagnosis program, 2010–2016. J Acquir Immune Deficiency Syndr 77 (2018), 212–216.
23. Palumbo, PE, Raskino, C, Fiscus, S, et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA 279 (1998), 756–761.
24. Abrams, EJ, Weedon, J, Steketee, RW, et al. Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group. J Infect Dis 178 (1998), 101–108.
25. Antunes, F, Zindoga, P, Gomes, P, et al. Development of nevirapine resistance in children exposed to the prevention of mother-to-child HIV-1 transmission programme in Maputo, Mozambique. PLoS One, 10, 2015, e0131994.
26. Kuhn, L, Hunt, G, Technau, KG, et al. Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. AIDS 28 (2014), 1673–1678.
27. Nachman, S, Alvero, C, Acosta, EP, et al. Pharmacokinetics and 48-week safety and efficacy of raltegravir for oral suspension in human immunodeficiency virus type-1-infected children 4 weeks to 2 years of age. J Pediatric Infect Dis Soc 4 (2015), e76–e83.
28. Goulder, PJ, Lewin, SR, Leitman, EM, Paediatric HIV infection: the potential for cure. Nat Rev Immunol 16 (2016), 259–271.